Evolving Strategies for Management of Early-Stage and Metastatic Triple-Negative Breast Cancer

Published Online:Jun 16, 2014
Release Date: June 02, 2014
Expiration Date: June 01, 2015

This activity is supported by an educational grant from Eisai, Inc.

Jointly provided by Dannemiller and Targeted Healthcare Communications.

dannemiller


Intended Audience
Oncologists, surgical oncologists, radiation oncologists, and oncology nurses.

Learning Objectives
Upon completion of this activity, the participant should be able to:
  • Review clinical trial data on current and emerging neoadjuvant treatments for patients with early-stage TNBC.
  • Evaluate efficacy and safety data for currently available chemotherapeutic agents for patients with metastatic TNBC.
  • Develop and implement individualized treatment plans with consideration for key patient and clinical factors for patients with TNBC.
Statement of Need
This activity is designed to educate oncologists and oncology nurses on evolving strategies for management of early-stage and metastatic triple-negative breast cancer. The discussion includes information regarding incidence, prognosis, and molecular subtypes of TNBC. It includes data on neoadjuvant treatment for early-stage TNBC, including benefits, such as improved pCR rates; and information on anthracycline-, taxane-, platinum-, and microtubule-inhibitor-based regimens. The CME also includes information on: recurrence and survival data and locations of metastases, treatment responses with chemotherapy, single-agent versus combination therapy, preferred NCCN single agents, and study 301 subgroup data. It details the factors to consider when selecting treatments, including: personalizing goals of chemotherapy in metastatic TNBC; tolerance of side effects; and quality-of-life considerations.

To continue this CME, click here.

JTT Articles
Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Biliary Cancer: Current Management and Emerging Targeted Therapies
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
$vAR$